Implants for drug delivery to the posterior segment of the eye: A focus on stimuli-responsive and tunable release systems

Journal of Controlled Release

Volumn 196, Issue , 2014, Pages 208-221

  Yasin, M Naveed ^a   Svirskis, Darren ^a   Seyfoddin, Ali ^a   Rupenthal, Ilva D ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Ocular drug delivery; Ocular implants; Retinal diseases; Smart polymers; Stimuli responsive systems

Indexed keywords

OCULAR DRUG DELIVERY; POSTERIOR SEGMENT; RETINAL DISEASE; SMART POLYMERS; STIMULI-RESPONSIVE; STIMULI-RESPONSIVE SYSTEMS;

AFLIBERCEPT; BETAMETHASONE; BEVACIZUMAB; BRIMONIDINE; CIDOFOVIR; CYCLOSPORIN A; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETANERCEPT; FLUOCINOLONE; FLUOCINOLONE ACETONIDE; FLUOROURACIL; FOSCARNET; GANCICLOVIR; INDOMETACIN; INFLIXIMAB; INTERFERON; POLYMER; RANIBIZUMAB; RAPAMYCIN; RENEXUS; TACROLIMUS; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VERISOME; DELAYED RELEASE FORMULATION; DRUG IMPLANT;

AGE RELATED MACULAR DEGENERATION; CONJUNCTIVA; CYTOMEGALOVIRUS RETINITIS; DIABETIC RETINOPATHY; DRUG DELIVERY SYSTEM; IMPLANT DELIVERY DEVICE; INTRAVITREAL IMPLANT; REVIEW; SCLERA; SUSTAINED DRUG RELEASE; UVEITIS; VITREORETINOPATHY; VITREOUS BODY; ANIMAL; DELAYED RELEASE FORMULATION; DRUG IMPLANT; EYE DISEASES; HUMAN; POSTERIOR EYE SEGMENT; PROCEDURES;

ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; EYE DISEASES; HUMANS; POSTERIOR EYE SEGMENT;

EID: 84908513901     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.09.030     Document Type: Review

References (167)

1. K. Ariga, K. Kawakami, M. Ebara, Y. Kotsuchibashi, Q. Ji, and J.P. Hill Bioinspired nanoarchitectonics as emerging drug delivery systems New J. Chem. 38 2014 5149 5163
2. G.C. Patel, and C.A. Dalwadi Recent patents on stimuli responsive hydrogel drug delivery system Recent Pat. Drug Deliv. Formul. 7 2013 206 215
3. S.J. Buwalda, K.W. Boere, P.J. Dijkstra, J. Feijen, T. Vermonden, and W.E. Hennink Hydrogels in a historical perspective: from simple networks to smart materials J. Control. Release 190 2014 254 273
4. I. Tomatsu, K. Peng, and A. Kros Photoresponsive hydrogels for biomedical applications Adv. Drug Deliv. Rev. 63 2011 1257 1266
5. S. Sortino Photoactivated nanomaterials for biomedical release applications J. Mater. Chem. 22 2012 301 318
6. A.T. Neffe, C. Wischke, M. Racheva, and A. Lendlein Progress in biopolymer-based biomaterials and their application in controlled drug delivery Expert Rev. Med. Devices 10 2013 813 833
7. U.B. Kompella, A.C. Amrite, R. Pacha Ravi, and S.A. Durazo Nanomedicines for back of the eye drug delivery, gene delivery, and imaging Prog. Retin. Eye Res. 36 2013 172 198
8. A.L. Wells, and H. Sheardown Photoresponsive polymers for ocular drug delivery D. Thassu, J.G. Chader, Ocular Drug Delivery Systems 2012 CRC Press 383 400
9. D.S. Boyer, P.A. Campochiaro, M.S. Humayun, L. Schopf, S.D. Vold, and B. Wirostko Emerging technologies approach complex eye diseases from new directions Ocul. Surg. News APAO 8-22 May 2014
10. J. Wyatt, and J. Rizzo Ocular implants for the blind IEEE 33 1996 47 53
11. H. Oubraham, S.Y. Cohen, S. Samimi, D. Marotte, I. Bouzaher, and P. Bonicel Inject and extend dosing versus dosing as needed a comparative retrospective study of ranibizumab in exudative age-related macular degeneration Retina 31 2011 26 30
12. T.R. Thrimawithana, S. Young, C.R. Bunt, C. Green, and R.G. Alany Drug delivery to the posterior segment of the eye Drug Discov. Today 16 2011 270 277
13. D.A. Jabs Treatment of cytomegalovirus retinitis Arch. Ophthalmol. 110 1992 185 187
14. G.J. Jaffe, D. Martin, D. Callanan, P.A. Pearson, B. Levy, and T. Comstock Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study Ophthalmology 113 2006 1020 1027
15. D.C. Musch, D.F. Martin, J.F. Gordon, M.D. Davis, B.D. Kuppermann, and M.H. Heinemann Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant N. Engl. J. Med. 337 1997 83 90
16. J. Wang, A. Jiang, M. Joshi, and J. Christoforidis Drug delivery implants in the treatment of vitreous inflammation Mediat. Inflamm. 2013 2013 780634
17. N. Haghjou, M. Soheilian, and M.J. Abdekhodaie Sustained release intraocular drug delivery devices for treatment of uveitis J. Ophthalmic Vis. Res. 6 2011 317 329
18. http://www.psivida.com/products-iluvien.html (last accessed on June 9, 2014. Perma link: http://perma.cc/4WYV-AA5D)
19. E. Meng, and T. Hoang MEMS-enabled implantable drug infusion pumps for laboratory animal research, preclinical, and clinical applications Adv. Drug Deliv. Rev. 64 2012 1628 1638
20. A.K. Dash, and G.C. Cudworth II Therapeutic applications of implantable drug delivery systems J. Pharmacol. Toxicol. Methods 40 1998 1 12
21. G.A. Lalwani, P.J. Rosenfeld, A.E. Fung, S.R. Dubovy, S. Michels, and W. Feuer A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study Am J. Ophthalmol. 148 2009 43 58
22. Y.C. Kim, B. Chiang, X. Wu, and M.R. Prausnitz Ocular delivery of macromolecules J. Control. Release 190 2014 172 181
23. D. Shiino, Y. Murata, K. Kataoka, Y. Koyama, M. Yokoyama, T. Okano, and Y. Sakurai Preparation and characterization of a glucose-responsive insulin-releasing polymer device Biomaterials 15 1994 121 128
24. J. Kost, and R. Langer Responsive polymeric delivery systems Adv. Drug Deliv. Rev. 64 2012 327 341
25. D. Pascolini, and S.P. Mariotti Global estimates of visual impairment: 2010 Br. J. Ophthalmol. 96 2012 614 618
26. J.L. Edelman Differentiating intraocular glucocorticoids Ophthalmologica 224 Suppl. 1 2010 25 30
27. N. Kuno, and S. Fujii Biodegradable intraocular therapies for retinal disorders: progress to date Drugs Aging 27 2010 117 134
28. N. Kuno, and S. Fujii Ocular drug delivery systems for the posterior segment: a review Retina Today May/June 2012 54 59
29. http://clinicaltrials.gov/ct2/show/NCT00658619 (last accessed on June 9, 2014, [Perma link: http://perma.cc/E94X-YWPA ])
30. S. Azadi, L.E. Johnson, F. Paquet-Durand, M.T. Perez, Y. Zhang, P.A. Ekstrom, and T. van Veen CNTF + BDNF treatment and neuroprotective pathways in the rd1 mouse retina Brain Res. 1129 2007 116 129
31. M. Zhang, X. Mo, Y. Fang, W. Guo, J. Wu, S. Zhang, and Q. Huang Rescue of photoreceptors by BDNF gene transfer using in vivo electroporation in the RCS rat of retinitis pigmentosa Curr. Eye Res. 34 2009 791 799
32. K. Zhang, J.J. Hopkins, J.S. Heier, D.G. Birch, L.S. Halperin, and T.A. Albini Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration Proc. Natl. Acad. Sci. U. S. A. 108 2011 6241 6245
33. R. Lo, P.Y. Li, S. Saati, R.N. Agrawal, M.S. Humayun, and E. Meng A passive MEMS drug delivery pump for treatment of ocular diseases Biomed. Microdevices 11 2009 959 970
34. S. Saati, R. Lo, P.Y. Li, E. Meng, R. Varma, and M.S. Humayun Mini drug pump for ophthalmic use Trans. Am. Ophthalmol. Soc. 107 2009 60 70
35. J.R. Coppeta, K.N. Horne, A. Poutiatine, J.T. Santini Jr, J.A. Scholl, N. Shams, G.J. Spooner, C.L. Stevenson, Low-permeability, laser-activated drug delivery device, US Patent 13/023,370 B1, 09/02/2012.
36. S.A. Molokhia, H. Sant, J. Simonis, C.J. Bishop, R.M. Burr, B.K. Gale, and B.K. Ambati The capsule drug device: novel approach for drug delivery to the eye Vis. Res. 50 2010 680 685
37. F.N. Pirmoradi, J.K. Jackson, H.M. Burt, and M. Chiao On-demand controlled release of docetaxel from a battery-less MEMS drug delivery device Lab Chip 11 2011 2744 2752
38. T. Navratil, B. Maynor, and B. Yerxa Improving outcomes in ophthalmology via sustained drug delivery ONdrugDelivery 48 2014 10 13
39. D.A. Bernards, R.B. Bhisitkul, and T. Desai Zero-order sustained drug delivery to the retina from a nanoporous film device ONdrugDelivery 48 2014 20 21
40. D.A. Jabs, C. Enger, and J.G. Bartlett Cytomegalovirus retinitis and acquired immunodeficiency syndrome Arch. Ophthalmol. 107 1989 75 80
41. J.G. Gross, S.A. Bozzette, W.C. Mathews, S.A. Spector, I.S. Abramson, and J.A. McCutchan Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome Ophthalmology 97 1990 681 686
42. A.G. Palestine, M.M. Rodrigues, A.M. Macher, C.C. Chan, H.C. Lane, and A.S. Fauci Ophthalmic involvement in acquired immunodeficiency syndrome Ophthalmology 91 1984 1092 1099
43. W.W. Culbertson Infections of the retina in AIDS Int. Ophthalmol. Clin. 29 1989 108 118
44. D.E. Henderly, W.R. Freeman, D.M. Causey, and N.A. Rao Cytomegalovirus retinitis and response to therapy with ganciclovir Ophthalmology 94 1987 425 434
45. H.L. Cantrill, K. Henry, N.H. Melroe, W.H. Knobloch, R.C. Ramsay, and H.H. Balfour Jr. Treatment of cytomegalovirus retinitis with intravitreal ganciclovir. Long-term results Ophthalmology 96 1989 367 374
46. T.J. Smith, P.A. Pearson, D.L. Blandford, J.D. Brown, K.A. Goins, and J.L. Hollins Intravitreal sustained-release ganciclovir Arch. Ophthalmol. 110 1992 255 258
47. A.P. Limaye, L. Corey, D.M. Koelle, C.L. Davis, and M. Boeckh Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants Lancet 356 2000 645 649
48. G.E. Sanborn, R. Anand, R.E. Torti, S.D. Nightingale, S.X. Cal, and B. Yates Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device Arch. Ophthalmol. 110 1992 188 195
49. M.A. Jacobson, W.L. Drew, J. Feinberg, J.J. O'Donnell, P.V. Whitmore, R.D. Miner, and D. Parenti Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS J. Infect. Dis. 163 1991 1348 1351
50. M.A. Jacobson Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome N. Engl. J. Med. 337 1997 1019
51. I. Taskintuna, F.M. Rahhal, J.F. Arevalo, D. Munguia, A.S. Banker, E. De Clercq, and W.R. Freeman Low-dose intravitreal cidofovir (HPMPC) therapy of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome Ophthalmology 104 1997 1049 1057
52. I.L. Smith, I. Taskintuna, F.M. Rahhal, H.C. Powell, E. Ai, and A.J. Mueller Clinical failure of CMV retinitis with intravitreal cidofovir is associated with antiviral resistance Arch. Ophthalmol. 116 1998 178 185
53. D. Pascolini, S.P. Mariotti, G.P. Pokharel, R. Pararajasegaram, D. Etya'ale, A.D. Negrel, and S. Resnikoff 2002 global update of available data on visual impairment: a compilation of population-based prevalence studies Ophthalmic Epidemiol. 11 2004 67 115
54. C.F. Chou, M.F. Cotch, S. Vitale, X. Zhang, R. Klein, and D.S. Friedman Age-related eye diseases and visual impairment among U.S. adults Am. J. Prev. Med. 45 2013 29 35
55. R. Klein, and B.E. Klein The prevalence of age-related eye diseases and visual impairment in aging: current estimates Invest. Ophthalmol. Vis. Sci. 54 2013 5 13
56. F.L. Ferris III, S.L. Fine, and L. Hyman Age-related macular degeneration and blindness due to neovascular maculopathy Arch. Ophthalmol. 102 1984 1640 1642
57. H.R. Coleman, C.C. Chan, F.L. Ferris III, and E.Y. Chew Age-related macular degeneration Lancet 372 2008 1835 1845
58. R.D. Jager, W.F. Mieler, and J.W. Miller Age-related macular degeneration N. Engl. J. Med. 358 2008 2606 2617
59. (R)): a review of its use in patients with macular oedema secondary to central retinal vein occlusion Drugs Aging 31 2014 395 404
60. J.B. Jonas, R.F. Degenring, I. Kreissig, T. Friedemann, and I. Akkoyun Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study Eye 19 2005 163 170
61. J. Xu, Y. Wang, Y. Li, X. Yang, P. Zhang, and H. Hou Inhibitory efficacy of intravitreal dexamethasone acetate-loaded PLGA nanoparticles on choroidal neovascularization in a laser-induced rat model J. Ocul. Pharmacol. Ther. 23 2007 527 540
62. http://www.clinicaltrial.gov/ct2/show/NCT00032396?term=A+Study+to+Evaluate+Retisert+in+the+Treatment+of+Patients+With+the+%22Wet%22+Form+of+Age-Related+Macular+Degeneration&rank=1 (last accessed on June 9, 2014, [Perma link: http://perma.cc/6EVN-X5JE)
63. http://www.clinicaltrials.gov/ct2/show/NCT00605423?term=psivida&rank=2 (last accessed on June 9, 2014, [Perma link: http://perma.cc/Z2BA-Y4US ])
64. L. Wu, M.A. Martinez-Castellanos, H. Quiroz-Mercado, J.F. Arevalo, M.H. Berrocal, and M.E. Farah Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES) Graefes Arch. Clin. Exp. Ophthalmol. 246 2008 81 87
65. http://www.clinicaltrial.gov/ct2/show/NCT01014468?term=bevacizumab+age+related+macular+degeneration&rank=5 (last accessed on June 9, 2014, [Perma link: http://perma.cc/UP6M-VBFS ])
66. http://www.clinicaltrial.gov/ct2/show/NCT00531024?term=bevacizumab+age+related+macular+degeneration&rank=13 (last accessed on June 9, 2014, [Perma link: http://perma.cc/5A5Y-2SGZ ])
67. A.J. Augustin, S. Puls, and I. Offermann Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone Retina 27 2007 133 140
68. M.M. Engelgau, L.S. Geiss, J.B. Saaddine, J.P. Boyle, S.M. Benjamin, and E.W. Gregg The evolving diabetes burden in the United States Ann. Intern. Med. 140 2004 945 950
69. J.M. Lopes de Faria, A.E. Jalkh, C.L. Trempe, and J.W. McMeel Diabetic macular edema: risk factors and concomitants Acta Ophthalmol. Scand. 77 1999 170 175
70. M.W. Johnson Etiology and treatment of macular edema Am J. Ophthalmol. 147 2009 11 21
71. Q.A. Mohamed, A. Ross, and C.J. Chu Diabetic retinopathy (treatment) Clin. Evid. (Online) 2011 2011 0702
72. R. Bansal, P. Bansal, P. Kulkarni, V. Gupta, A. Sharma, and A. Gupta Wandering Ozurdex® implant J. Ophthalmic Inflamm. Infect. 2 2012 1 5
73. D.F. Kiernan, and W.F. Mieler The use of intraocular corticosteroids Expert. Opin. Pharmacother. 10 2009 2511 2525
74. J.C. Pastor Proliferative vitreoretinopathy: an overview Surv. Ophthalmol. 43 1998 3 18
75. P.E. Rubsamen, P.A. Davis, E. Hernandez, G.E. O'Grady, and S.W. Cousins Prevention of experimental proliferative vitreoretinopathy with a biodegradable intravitreal implant for the sustained release of fluorouracil Arch. Ophthalmol. 112 1994 407 413
76. C.S. Yang, J.A. Khawly, D.P. Hainsworth, S.N. Chen, P. Ashton, H. Guo, and G.J. Jaffe An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy Arch. Ophthalmol. 116 1998 69 77
77. M.H. Rahimy, G.A. Peyman, M.L. Fernandes, S.H. el-Sayed, Q. Luo, and H. Borhani Effects of an intravitreal daunomycin implant on experimental proliferative vitreoretinopathy: simultaneous pharmacokinetic and pharmacodynamic evaluations J. Ocul. Pharmacol. 10 1994 561 570
78. L.B. Enyedi, P.A. Pearson, P. Ashton, and G.J. Jaffe An intravitreal device providing sustained release of cyclosporine and dexamethasone Curr. Eye Res. 15 1996 549 557
79. M. Hashizoe, Y. Ogura, T. Takanashi, N. Kunou, Y. Honda, and Y. Ikada Implantable biodegradable polymeric device in the treatment of experimental proliferative vitreoretinopathy Curr. Eye Res. 14 1995 473 477
80. T. Zhou, H. Lewis, R.E. Foster, and S.P. Schwendeman Development of a multiple-drug delivery implant for intraocular management of proliferative vitreoretinopathy J. Control. Release 55 1998 281 295
81. J.A. Cardillo, M.E. Farah, J. Mitre, P.H. Morales, R.A. Costa, and L.A. Melo An intravitreal biodegradable sustained release naproxen and 5-fluorouracil system for the treatment of experimental post-traumatic proliferative vitreoretinopathy Br. J. Ophthalmol. 88 2004 1201 1205
82. A.S. Berger, C.K. Cheng, P.A. Pearson, P. Ashton, P.A. Crooks, and T. Cynkowski Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy Invest. Ophthalmol. Vis. Sci. 37 1996 2318 2325
83. A. Sadaka, and G.P. Giuliari Proliferative vitreoretinopathy: current and emerging treatments Clin. Ophthalmol. 6 2012 1325 1333
84. E. Bloch-Michel, and R.B. Nussenblatt International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease Am J. Ophthalmol. 103 1987 234 235
85. K.D. Frick, L.T. Drye, J.H. Kempen, J.P. Dunn, G.N. Holland, and P. Latkany Associations among visual acuity and vision- and health-related quality of life among patients in the multicenter uveitis steroid treatment trial Invest. Ophthalmol. Vis. Sci. 53 2012 1169 1176
86. E. Pato, S. Munoz-Fernandez, F. Francisco, M.A. Abad, J. Maese, A. Ortiz, and L. Carmona Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis Semin. Arthritis Rheum. 40 2011 314 323
87. P. Lin, E.B. Suhler, and J.T. Rosenbaum The future of uveitis treatment Ophthalmology 121 2014 365 376
88. N. Kunou, Y. Ogura, Y. Honda, S.H. Hyon, and Y. Ikada Biodegradable scleral implant for controlled intraocular delivery of betamethasone phosphate J. Biomed. Mater. Res. 51 2000 635 641
89. A. Urtti Challenges and obstacles of ocular pharmacokinetics and drug delivery Adv. Drug Deliv. Rev. 58 2006 1131 1135
90. P.N. Bishop Structural macromolecules and supramolecular organisation of the vitreous gel Prog. Retin. Eye Res. 19 2000 323 344
91. J.L. Bourges, C. Bloquel, A. Thomas, F. Froussart, A. Bochot, and F. Azan Intraocular implants for extended drug delivery: therapeutic applications Adv. Drug Deliv. Rev. 58 2006 1182 1202
92. Y.E. Choonara, V. Pillay, M.P. Danckwerts, T.R. Carmichael, and L.C. du Toit A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases J. Pharm. Sci. 99 2010 2219 2239
93. S. Duvvuri, S. Majumdar, and A.K. Mitra Drug delivery to the retina: challenges and opportunities Expert. Opin. Biol. Ther. 3 2003 45 56
94. C.L. Schepens, and F. Acosta Scleral implants: an historical perspective Surv. Ophthalmol. 35 1991 447 453
95. E. de Juan Jr, Y. Alster, K.C. Farinas, K.A. Macfarlane, C.J. Reich, R.E. Campbell, Implantable therapeutic device, US Patent 13/204,638, 19/04/2012.
96. E. de Juan Jr, Y. Alster, K.C. Farinas, K.A. Macfarlane, C.J. Reich, R.E. Campbell, Implantable therapeutic device, US Patent 13/204,638, 07/01/2014.
97. G.S. Kalsi, H.K. Silver, and J. Rootman Ocular pharmacokinetics of dacarbazine following subconjunctival versus intravenous administration in the rabbit Can. J. Ophthalmol. 26 1991 247 251
98. Y. Peng, M. Ang, S. Foo, W.S. Lee, Z. Ma, S.S. Venkatraman, and T.T. Wong Biocompatibility and biodegradation studies of subconjunctival implants in rabbit eyes PLoS ONE 6 2011 e22507
99. N. Nagai, H. Kaji, H. Onami, Y. Ishikawa, M. Nishizawa, and N. Osumi A polymeric device for controlled transscleral multi-drug delivery to the posterior segment of the eye Acta Biomater. 10 2014 680 687
100. W.B. Liechty, D.R. Kryscio, B.V. Slaughter, and N.A. Peppas Polymers for drug delivery systems Annu. Rev. Chem. Biomol. Eng. 1 2010 149 173
101. W.W. Yang, and E. Pierstorff Reservoir-based polymer drug delivery systems J. Lab. Autom. 17 2012 50 58
102. R. da Silva, S.L. Fialho, R.C. Siqueira, R. Jorge, and A. da Silva Cunha Júnior Implants as drug delivery devices for the treatment of eye diseases Braz. J. Pharm. Sci 46 2010 585 595
103. M.H. Rahimy, G.A. Peyman, S.Y. Chin, R. Golshani, C. Aras, H. Borhani, and H. Thompson Polysulfone capillary fiber for intraocular drug delivery: in vitro and in vivo evaluations J. Drug Target. 2 1994 289 298
104. http://www.neurotechusa.com/ect-platform.html (last accessed on June 9, 2014, [Perma link: http://perma.cc/R5R3-Y4YC ])
105. D.F. Martin, D.J. Parks, S.D. Mellow, F.L. Ferris, R.C. Walton, and N.A. Remaley Treatment of cytomegalovirus retinitis with an intraocular sustained-release ganciclovir implant. A randomized controlled clinical trial Arch. Ophthalmol. 112 1994 1531 1539
106. J.I. Lim, R.A. Wolitz, A.H. Dowling, H.R. Bloom, A.R. Irvine, and D.M. Schwartz Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis Am J. Ophthalmol. 127 1999 288 293
107. G.J. Jaffe, C.H. Yang, H. Guo, J.P. Denny, C. Lima, and P. Ashton Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device Invest. Ophthalmol. Vis. Sci. 41 2000 3569 3575
108. D.A. Mohammad, B.V. Sweet, and S.G. Elner Retisert: is the new advance in treatment of uveitis a good one? Ann. Pharmacother. 41 2007 449 455
109. C.G. Thanos, W.J. Bell, P. O'Rourke, K. Kauper, S. Sherman, P. Stabila, and W. Tao Sustained secretion of ciliary neurotrophic factor to the vitreous, using the encapsulated cell therapy-based NT-501 intraocular device Tissue Eng. 10 2004 1617 1622
110. D.G. Birch, R.G. Weleber, J.L. Duncan, G.J. Jaffe, and W. Tao Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa Am J. Ophthalmol. 156 2013 283 292
111. F.E. Kane, J. Burdan, A. Cutino, and K.E. Green Iluvien: a new sustained delivery technology for posterior eye disease Expert Opin. Drug Deliv. 5 2008 1039 1046
112. P.A. Pearson, T.L. Comstock, M. Ip, D. Callanan, L.S. Morse, and P. Ashton Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial Ophthalmology 118 2011 1580 1587
113. C.L. Stevenson, J.T. Santini Jr., and R. Langer Reservoir-based drug delivery systems utilizing microtechnology Adv. Drug Deliv. Rev. 64 2012 1590 1602
114. S.L. Fialho, and A.D. Cunha Manufacturing techniques of biodegradable implants intended for intraocular application Drug Deliv. 12 2005 109 116
115. R. Chandra, and R. Rustgi Biodegradable polymers Prog. Polym. Sci. 23 1998 1273 1335
116. R. Herrero-Vanrell, I. Bravo-Osuna, V. Andres-Guerrero, M. Vicario-de-la-Torre, and I.T. Molina-Martinez The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies Prog. Retin. Eye Res. 42 2014 27 43
117. T. Yasukawa, Y. Ogura, E. Sakurai, Y. Tabata, and H. Kimura Intraocular sustained drug delivery using implantable polymeric devices Adv. Drug Deliv. Rev. 57 2005 2033 2046
118. X. Dong, W. Shi, G. Yuan, L. Xie, S. Wang, and P. Lin Intravitreal implantation of the biodegradable cyclosporin A drug delivery system for experimental chronic uveitis Graefes Arch. Clin. Exp. Ophthalmol. 244 2006 492 497
119. W. Shi, T. Liu, L. Xie, and S. Wang FK506 in a biodegradable glycolide-co-clatide-co-caprolactone polymer for prolongation of corneal allograft survival Curr. Eye Res. 30 2005 969 976
120. S. Einmahl, F. Behar-Cohen, C. Tabatabay, M. Savoldelli, F. D'Hermies, and D. Chauvaud A viscous bioerodible poly(ortho ester) as a new biomaterial for intraocular application J. Biomed. Mater. Res. 50 2000 566 573
121. K.W. Leong, B.C. Brott, and R. Langer Bioerodible polyanhydrides as drug-carrier matrices. I: characterization, degradation, and release characteristics J. Biomed. Mater. Res. 19 1985 941 955
122. M. Rourke, and J. Hanes Ocular drug delivery via micro and nanoparticles Retina Today July/August 2014 84 87
123. M. Rourke, J. Hanes, P.A. Campochiaro, and P. McDonnel GrayBug ONdrugDelivery 48 2014 8 9
124. http://iconbioscience.com/ibi-20089 (last accessed on June 9, 2014, [Perma link: http://perma.cc/XJ7J-MJFK ])
125. S.S. Lee, P. Hughes, A.D. Ross, and M.R. Robinson Biodegradable implants for sustained drug release in the eye Pharm. Res. 27 2010 2043 2053
126. D. Pardo-Lopez, E. Frances-Munoz, R. Gallego-Pinazo, and M. Diaz-Llopis Anterior chamber migration of dexametasone intravitreal implant (Ozurdex®) Graefes Arch. Clin. Exp. Ophthalmol. 250 2012 1703 1704
127. F.S. Ong, J.Z. Kuo, W. Wu, C. Cheng, W.B. Blackwell, B.L. Taylor, W.W. Grody, J.I. Rotter, C. Lai, and T.Y. Wong Personalized medicine in ophthalmology: from pharmacogenetic biomarkers to therapeutic and dosage optimization J. Pers. Med. 3 2013 40 69
128. J.G. Christie, and U.B. Kompella Ophthalmic light sensitive nanocarrier systems Drug Discov. Today 13 2008 124 134
129. J.Q. Jiang, X. Tong, D. Morris, and Y. Zhao Toward photocontrolled release using light-dissociable block copolymer micelles Macromolecules 39 2006 4633 4640
130. P. Juzenas, A. Juzeniene, O. Kaalhus, V. Iani, and J. Moan Noninvasive fluorescence excitation spectroscopy during application of 5-aminolevulinic acid in vivo Photochem. Photobiol. Sci. 1 2002 745 748
131. A. Mamada, T. Tanaka, D. Kungwatchakun, and M. Irie Photoinduced phase-transition of gels Macromolecules 23 1990 1517 1519
132. J.Q. Jiang, X. Tong, and Y. Zhao A new design for light-breakable polymer micelles J. Am. Chem. Soc. 127 2005 8290 8291
133. C.J. Rijcken, O. Soga, W.E. Hennink, and C.F. van Nostrum Triggered destabilisation of polymeric micelles and vesicles by changing polymers polarity: an attractive tool for drug delivery J. Control. Release 120 2007 131 148
134. K. Peng, I. Tomatsu, B. van den Broek, C. Cui, A.V. Korobko, and J. van Noort Dextran based photodegradable hydrogels formed via a Michael addition Soft Matter 7 2011 4881 4887
135. L.R. Hirsch, R.J. Stafford, J.A. Bankson, S.R. Sershen, B. Rivera, and R.E. Price Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance Proc. Natl. Acad. Sci. U. S. A. 100 2003 13549 13554
136. A.G. MacDiarmid "Synthetic metals": a novel role for organic polymers (Nobel lecture) Angew. Chem. Int. Ed. 40 2001 2581 2590
137. S. Geetha, C.R.K. Rao, M. Vijayan, and D.C. Trivedi Biosensing and drug delivery by polypyrrole Anal. Chim. Acta. 568 2006 119 125
138. D. Svirskis, B.E. Wright, J. Travas-Sejdic, A. Rodgers, and S. Garg Development of a controlled release system for risperidone using polypyrrole: mechanistic studies Electroanalysis 22 2010 439 444
139. D. Svirskis, B.E. Wright, J. Travas-Sejdic, A. Rodgers, and S. Garg Evaluation of physical properties and performance over time of an actuating polypyrrole based drug delivery system Sensors Actuators B Chem. 151 2010 97 102
140. D. Svirskis, M. Sharma, Y. Yu, and S. Garg Electrically switchable polypyrrole film for the tunable release of progesterone Ther. Deliv. 4 2013 307 313
141. D. Svirskis, J. Travas-Sejdic, A. Rodgers, and S. Garg Electrochemically controlled drug delivery based on intrinsically conducting polymers J. Control. Release 146 2010 6 15
142. T.J. Rivers, T.W. Hudson, and C.E. Schmidt Synthesis of a novel, biodegradable electrically conducting polymer for biomedical applications Adv. Funct. Mater. 12 2002 33 37
143. M. Sharma, G.I.N. Waterhouse, S.W.C. Loader, S. Garg, and D. Svirskis High surface area polypyrrole scaffolds for tunable drug delivery Int. J. Pharm. 443 2013 163 168
144. D.T. Ge, X.D. Tian, R. Qi, S.Q. Huang, J. Mu, and S.M. Hong A polypyrrole-based microchip for controlled drug release Electrochim. Acta 55 2009 271 275
145. G. Valdes-Ramirez, J.R. Windmiller, J.C. Claussen, A.G. Martinez, F. Kuralay, and M. Zhou Multiplexed and switchable release of distinct fluids from microneedle platforms via conducting polymer nanoactuators for potential drug delivery Sensors Actuators B Chem. 161 2012 1018 1024
146. R. Wadhwa, C.F. Lagenaur, and X.T. Cui Electrochemically controlled release of dexamethasone from conducting polymer polypyrrole coated electrode J. Control. Release 110 2006 531 541
147. Y. Cho, R.Y. Shi, A. Ivanisevic, and R. Ben Borgens A mesoporous silica nanosphere-based drug delivery system using an electrically conducting polymer Nanotechnology 20 2009
148. W.B. Zhong, J.Y. Deng, Y.S. Yang, and W.T. Yang Synthesis of large-area three-dimensional polyaniline nanowire networks using a "soft template" Macromol. Rapid Commun. 26 2005 395 400
149. M.B. Cannell, R.P. Cooney, P. Kilmartin, C. Soeller, J. Travas-Sejdic, Microfabricated device, US Patent 11/989,984, 11/03/2010.
150. K.L. Morgan, A.M. Shelchuk, J.D. Snell, N. Holmström, J.R. Helland, Electroactive polymer-actuated peristaltic pump and medical lead incorporating such a pump, US Patent 11/404,268, 08/07/2008.
151. M. Sharma, D. Svirskis, and S. Garg Advances in drug-delivery systems based on intrinsically conducting polymers C. Alvarez-Lorenzo, A. Concheiro, Smart Materials for Drug Delivery 2013 Royal Society of Chemistry Cambridge 283 303
152. T.S. Tsai, V. Pillay, Y.E. Choonara, L.C. du Toit, G. Modi, D. Naidoo, and P. Kumar A polyvinyl alcohol-polyaniline based electro-conductive hydrogel for controlled stimuli-actuable release of indomethacin Polymers 3 2011 150 172
153. R. Farra, N.F. Sheppard, L. McCabe, R.M. Neer, J.M. Anderson, and J.T. Santini First-in-human testing of a wirelessly controlled drug delivery microchip Sci. Transl. Med. 4 2012
154. S. Brady, K.T. Lau, W. Megill, G.G. Wallace, and D. Diamond The development and characterisation of conducting polymeric-based sensing devices Synth. Met. 154 2005 25 28
155. S. Brady, D. Diamond, and K.T. Lau Inherently conducting polymer modified polyurethane smart foam for pressure sensing Sensors Actuators A Phys. 119 2005 398 404
156. O.C. Jeong, and S.S. Yang Fabrication and test of a thermopneumatic micropump with a corrugated p plus diaphragm Sensors Actuators A Phys. 83 2000 249 255
157. R. Zengerle, J. Ulrich, S. Kluge, M. Richter, and A. Richter A bidirectional silicon micropump Sensors Actuators A Phys. 50 1995 81 86
158. Y.C. Su, and L.W. Lin A water-powered micro drug delivery system J. Microelectromech. Syst. 13 2004 75 82
159. N.C. Tsai, and C.Y. Sue Review of MEMS-based drug delivery and dosing systems Sensors Actuators A Phys. 134 2007 555 564
160. R. Lo, P.Y. Li, S. Saati, R. Agrawal, M.S. Humayun, and E. Meng A refillable microfabricated drug delivery device for treatment of ocular diseases Lab Chip 8 2008 1027 1030
161. P.Y. Li, J. Shih, R. Lo, S. Saati, R. Agrawal, and M.S. Humayun An electrochemical intraocular drug delivery device Sensors Actuators A Phys. 143 2008 41 48
162. D.S.T. Hsieh, R. Langer, and J. Folkman Magnetic modulation of release of macromolecules from polymers Proc. Natl. Acad. Sci. U. S. A. 78 1981 1863 1867
163. J. Kost, R. Noecker, E. Kunica, and R. Langer Magnetically controlled release systems - effect of polymer composition J. Biomed. Mater. Res. 19 1985 935 940
164. O. Saslawski, C. Weingarten, J.P. Benoit, and P. Couvreur Magnetically responsive microspheres for the pulsed delivery of insulin Life Sci. 42 1988 1521 1528
165. E.R. Edelman, J. Kost, H. Bobeck, and R. Langer Regulation of drug release from polymer matrices by oscillating magnetic-fields J. Biomed. Mater. Res. 19 1985 67 83
166. J. Kost, J. Wolfrum, and R. Langer Magnetically enhanced insulin release in diabetic rats J. Biomed. Mater. Res. 21 1987 1367 1373
167. R.K. Verma, and S. Garg Drug delivery technologies and future directions Pharm. Technol. On-Line 25 2001 1 14